Skip to main content
. 2019 Dec 10;295(3):757–770. doi: 10.1074/jbc.RA119.011443

Figure 5.

Figure 5.

SMAP inhibition of tumor growth and changes to c-MYC expression is abrogated by mutation to c-MYC phosphodegron. A, tumor growth in a xenograft model of Daudi cell line expressing EGFP treated with DMA or SMAP1 twice a day. B, representative images of TUNEL staining in DMA- or SMAP1-treated Daudi–EGFP tumors. C, quantification of TUNEL in Daudi–EGFP tumors. D, Western blotting of untreated and treated tumor lysates for c-MYC in the Daudi–EGFP xenograft. E, quantification of c-MYC protein in DMA- and SMAP-treated Daudi–EGFP tumors in D, normalized to GAPDH. F, tumor growth in a xenograft model of Daudi cell line overexpressing c-MYC with a S62D mutation treated with DMA or SMAP1 twice a day. G, representative images of TUNEL staining in DMA- or SMAP1-treated tumors from the S62D xenograft. H, quantification of TUNEL in the S62D tumors. I, Western blotting of protein from tumor lysates for c-MYC from the S62D xenograft. J, quantification of c-MYC protein in DMA- and SMAP-treated tumors from the S62D xenograft in I normalized to GAPDH. Respective quantifications are represented as means ± S.D. *, p < 0.05; **, p < 0.01; ***, p < 0.001.